Search clinical trials for: Programmed Cell Death-1 (PD1, PD-1),

Total 93469 results

National Cancer Institute (NCI)

Completed

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin Lymphoma | Primary Central Nervous System Lymphoma | Gray-zone Lymphoma

United States
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Rapa Therapeutics LLC

Recruiting

RAPA-201 Therapy of Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Solid Tumor | Bladder Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Carcinoma of Unknown Primary | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx and other conditions

United States
University of Pennsylvania
Incyte Corporation

Active, not recruiting

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Glioblastoma

United States
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer | Endostatin

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Shanghai Ninth People's Hospital Affiliated to...
Fudan University; First Affiliated Hospital of Fujian Medical University; Tianjin... and other collaborators

Recruiting

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) (IMPORT)

Head and Neck Squamous Cell Carcinoma

China
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
NYU Langone Health
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC)

United States
Guangdong Association of Clinical Trials

Unknown

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Nsclc
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Taiho Pharmaceutical Co., Ltd.

Completed

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Gastric Cancer

Japan
Nanfang Hospital of Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Essential Tremor

China
University of Copenhagen
TrygFonden, Denmark; University College Copenhagen; Danske Regioner; 19 maternity... and other collaborators

Completed

The MAMAACT Intervention (MAMAACT)

Asphyxia | Health Literacy | Stillbirth | Apgar; 0-3 at 1 Minute | Apgar; 4-7 at 1 Minute

Denmark
Groupe Français de Pneumo-Cancérologie

Completed

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC)

Large Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)

France
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

Biliary Tract Carcinoma

China
Wuhan Union Hospital, China
Shanghai Cell Therapy Group Co.,Ltd

Unknown

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Non-small-cell Lung Cancer | Mesothelioma

China
Novartis Pharmaceuticals

Active, not recruiting

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)

Melanoma

Italy, Czechia, Germany, Hungary, Canada, United States, Argentina, Australia, Austria, France, Israel, Russian Federation, Spain, Sweden, United Kingdom, Thailand, Belgium, Brazil, Greece, Switzerland, Mexico, Netherlands, Denmark, C... and more
Kitasato University
Yokohama City University Medical Center; St. Marianna University School of... and other collaborators

Unknown

Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension

Hypertension | Type 2 Diabetes Mellitus

Japan
OSCAR Study
Japan Heart Foundation

Completed

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

Cardiovascular Diseases | Hypertension

Japan
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
University of Copenhagen
Hvidovre University Hospital; Aga Khan University; VU University of Amsterdam; Comprehensive...

Recruiting

The PartoMa Project: Enabling Best Post Possible Childbirth Care in Tanzania.

Cesarean Section Complications | Stillbirth | Delivery Complication | Delivery Delayed | Apgar; 0-3 at 1 Minute | Apgar; 4-7 at 1 Minute

Tanzania
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Lu Hua

Not yet recruiting

Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study

Breast Cancer Patients With Chronic Pain After Surgery

China
Cukurova University

Not yet recruiting

Effect of Mobile Application Usage on Drug Compliance After Thyroidectomy

Patient Acceptance of Health Care | Drug Compliance
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Advanced Solid Tumors

Tumors

France, United States, Denmark, Ireland, Italy, Turkey, United Kingdom, Canada, Brazil, Spain, Poland, Netherlands, Germany, Russian Federation, Austria, Finland, Norway, Switzerland
Uro-1 Medical

Not yet recruiting

Evaluation of a Soft Tissue Biopsy System for Trans-rectal and Trans-perineal Biopsy of the Prostate

Prostate Disease
Children's Hospital 1

Recruiting

Sutureless Closure for Primary Total Anomalous Pulmonary Venous Connection (TAPVC)

Total Anomalous Pulmonary Venous Connection | Pulmonary Venous Stenosis | Sutureless Closure

Vietnam
Alpha-1 Foundation

Completed

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) (PFT)

Chronic Obstructive Pulmonary Disease | Alpha-1 Antitrypsin Deficiency

United States, Puerto Rico
Changzhou No.2 People's Hospital

Not yet recruiting

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor
Xuhua Duan

Recruiting

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NSCLC

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Hepatocellular Carcinoma

China
Bristol-Myers Squibb

Completed

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Melanoma

United States, Belgium, Canada, Germany, Spain
Cairo University

Unknown

Clinical Evaluation of Pink Esthetic Score

Thin Gingiva
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966)

Biliary Tract Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Spain, Taiwan, Thailand, Turkey, United Kingdom
Incyte Corporation
Bristol-Myers Squibb

Terminated

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Lung Cancer

United States
The N.1 Institute for Health (N.1)
Acceset

Completed

A Study Protocol on Peer Digital Acceset (PDA) (PDA)

Mental Health Issue

Singapore
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
Fondazione Ricerca Traslazionale

Unknown

The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC) (PD-L1)

To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods
RenJi Hospital
BeiGene; Huidu Shanghai Medical Sciences Ltd

Recruiting

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (TACBIN-01)

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Antineoplastic Agents | Tislelizumab Antineoplastic Agents, Immunological

China
Memorial Sloan Kettering Cancer Center
Xencor, Inc.

Active, not recruiting

A Study of XmAb23104 in People With Sarcoma

Sarcoma

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Completed

A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

Breast Cancer | Neoplasm Metastasis

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy

Chemotherapy-Induced Nausea and Vomiting

Japan
Tianjin Medical University Second Hospital

Recruiting

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced

China

Search clinical trials for: Programmed Cell Death-1 (PD1, PD-1),

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations